TABLE 4.
Major Published Series on EGD After LDLT
| Author/Year/Journal | Study Type | Country | N | MELD Score | EGD Criteria | EGD Incidence | Graft Loss |
|---|---|---|---|---|---|---|---|
| Pomposelli et al.6 2016 (A2ALL study) Transplantation |
Prospective | US and Canada | 631 | A2ALL-1 15.2 ± 5.4 A2ALL-2 15.8 ± 6.0 |
Bilirubin >10 mg/dL or INR >1.6 On POD 7 |
A2ALL-1:16% A2ALL-2:19% |
24% |
| Chae et al.15 2016 Ann Transplant |
Retrospective | Korea | 104 | EGD group 22.0 (12.0–30.0) Non-EGD group 13.5 (8.0–24.5) |
Olthoff’s Criteria |
29.8% | NA |
| Yadav et al.16 2017 Clinical Transplantation |
Retrospective | India | 151 849 |
≥25 <25 |
Olthoff’s Criteria |
25.2% 15.2% |
NA NA |
| Yang et al.17 2017 Hepatobiliary Pancreat Dis Int |
Retrospective | China | 231 | 20 (12–28) | Olthoff’s Criteria |
38.6% | 28.1% |
| Okamura et al.7 2018 Transplantation |
Retrospective | Japan | 260 | 18 (6–46) | TB of 10 mg/dL or greater and/or PT-INR of 1.6 or greater on POD 7 |
32.3% | 59% |
| Tasai et al.18 2021 Am J Transl Res |
Prospective | Taiwan | 74 | EGD group (21.22 ± 11.19) Non-EGD group (16.41 ± 8.37) |
Olthoff’s criteria |
29.7% | 22.7% |
| Singh et al.19 2022 Transplantation |
Prospective | India | 135 | 16 (6–45) | A2ALL study | 29.6% | 4.4% |
| Present study 2023 |
Retrospective | India | 387 | 24.9 ± 5.4 | Bilirubin ≥10 mg/dL and/or INR ≥1.6 on POD7, excluding vascular, biliary, infectious, and immunological causes | 33% | 9% |
EGD = early graft dysfunction; INR = international normalized ratio; MELD = model for end-stage liver disease; POD = postoperative day.